FDA label
What is Erleada used for?
Erleada contains apalutamide. The FDA-approved uses below are quoted from the Indications and Usage section of its DailyMed label.
Source: DailyMed SPL label file dated 2026-10-23. Publisher page
The FDA label says: “ERLEADA is indicated for the treatment of patients with”
Run it in Rivvi
Which 2027 plans near you dropped or restricted Erleada?
Tier changes and new prior auth, step therapy or quantity limits, plan by plan.
Free to start. Opens Rivvi, the AI workspace for healthcare teams.
Erleada, tablet, film coated
Indications and Usage, quoted from the label by Janssen Products, LP (NDA210951). Cross-references to other label sections are left out.
ERLEADA is indicated for the treatment of patients with
- Metastatic castration-sensitive prostate cancer (mCSPC)
- Non-metastatic castration-resistant prostate cancer (nmCRPC)
Source: DailyMed label, set id d1cda4f7-cb33-46ea-b9ac-431f6452b1a5, version 29, effective July 2, 2026. NDC 59676-600, one of 2 listings for this product.
Questions
What is Erleada used for?
The FDA label says: “ERLEADA is indicated for the treatment of patients with”
Does this page cover off-label uses or dosing?
No. This page shows only the Indications and Usage section of the FDA label. Ask a pharmacist or prescriber about dosing.